Speech, Language and Hearing · Jul 2025
Published RCT reporting statistically significant improvements for Oto versus wait-list control in Australian adults with chronic tinnitus.
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Oto is a London-based digital health company focused on tinnitus: it combines clinician-led care with a CBT-based mobile app and provider workflow for independent audiology practices and self-pay consumers.
Primary product
CBT-based tinnitus management app and provider program (Oto / Oto Pro)
Founded
2019
Headquarters
45 Fitzroy Street, Silverstream House, London W1T 6EB, United Kingdom
Team size
1-10
Work style
Hybrid
Industry
Wellness and Fitness Services
Sub-industry
Digital health / digital therapeutics for tinnitus
Offices
0 jobs at Oto
Check back later for new openings
Business model
Leadership
Co-Founder & CEO
Co-Founder
Co-Founder & CSO
Founding Head of Clinical Operations
Provider Audiologist, Onboarding Lead
Investors
Mission-driven, clinically focused, data-driven startup culture; small team that works closely with founders and clinicians, with emphasis on evidence-based care and rapid product iteration.
Work style
Hybrid
Compensation
A public product-manager listing showed £60k-£90k salary, EMI options, 25 days annual leave, L&D budget, MacBook, remote working budget, and flexible hours. No public visa policy was found.
Benefits
Pricing
Subscription; consumer self-pay via app stores plus provider-led program access for audiology practices and participating healthcare providers
Differentiators
Technology
Customers
Competitors
Estimated revenue
US$1M-US$10M
Estimated monthly visits
38K
Traffic estimate as of Jul 2026
Speech, Language and Hearing · Jul 2025
Published RCT reporting statistically significant improvements for Oto versus wait-list control in Australian adults with chronic tinnitus.
DigitalHealth.London · Jan 2025
Profile/interview describing Oto Health’s push into NHS collaborations, its DTAC/DSPT readiness, and plans around the DEFINE study.
PLOS ONE · Jan 2024
Protocol paper for the remote Cambridge-led randomized controlled trial comparing the Oto app with therapist-delivered tinnitus care.
Lindus Health · Sep 2023
Announcement of the fully remote DEFINE trial, including its 198-patient UK design and partnership with Cambridge.
Tech Funding News · Jul 2022
Seed-round coverage confirming the $3.3M raise and naming Octopus Ventures, Goodwater Capital, Y Combinator, Calm Storm Ventures, and Bethnal Green Ventures among the backers.